Exascale Labs Holdings Inc. (XLAB) Income Statement
XLAB FY2025 at a glance
Fiscal year ended June 30, 2025 · U.S. dollarsXLAB revenue and net income
Where XLAB's revenue goes
FY2025Each bar shows an amount and its share of revenue. XLAB kept −109.2% of revenue as net income.
XLAB profit margins
XLAB growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +431.8% | — | — | — |
| Gross profit | +1,888.9% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
XLAB quarterly EPS vs estimates
XLAB income statement
| FY2025 | FY2024 | |
|---|---|---|
| Revenue | $7.0M | $1.3M |
| Cost of revenue | $5.9M | $1.3M |
| Gross profit | $1.1M | $55,567 |
| Research & development | $2.8M | $1.4M |
| Sales, general & admin | $1.4M | $535,963 |
| Total operating expenses | $10.1M | $3.2M |
| Operating income | −$3.0M | −$1.8M |
| Income before taxes | −$7.7M | −$5.0M |
| Net income | −$7.7M | −$5.0M |
| EBITDA | −$3.0M | −$1.8M |
| EPS (diluted) | −$0.12 | — |
| Gross margin | 15.8% | 4.2% |
| Operating margin | −43.4% | −139.9% |
| Net margin | −109.2% | −375.7% |
| Mar '26 | Dec '25 | Jun '25 | Mar '25 | Dec '24 | |
|---|---|---|---|---|---|
| Revenue | $3.8M | $3.5M | $2.5M | $1.9M | $1.4M |
| Cost of revenue | $3.2M | $3.0M | $2.1M | $1.6M | $1.2M |
| Gross profit | $586,927 | $520,459 | $456,756 | $213,081 | $251,318 |
| Research & development | $1.2M | $1.1M | $682,053 | $377,999 | $335,853 |
| Sales, general & admin | $573,425 | $370,841 | $357,064 | $481,618 | $333,113 |
| Total operating expenses | $5.0M | $4.5M | $3.1M | $2.5M | $1.9M |
| Operating income | −$1.2M | −$988,004 | −$582,361 | −$646,536 | −$417,648 |
| Income before taxes | −$2.6M | −$3.8M | −$1.5M | −$1.5M | −$1.6M |
| Net income | −$2.6M | −$3.8M | −$1.5M | −$1.5M | −$1.6M |
| EBITDA | −$1.2M | −$988,004 | −$580,760 | −$644,935 | −$417,648 |
| EPS (diluted) | $0.05 | $0.06 | — | — | — |
| Gross margin | 15.6% | 14.7% | 18.0% | 11.4% | 17.4% |
| Operating margin | −32.5% | −27.9% | −22.9% | −34.7% | −29.0% |
| Net margin | −70.1% | −106.2% | −58.3% | −82.5% | −111.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in XLAB's financial statements (latest annual report filed —); data from EODHD. Sales, general & administrative expenses include sales and marketing.
XLAB financial results
In fiscal year 2025 (ended June 30, 2025), Exascale Labs reported revenue of $7.0 million, up 431.8% from the year before. It had a net loss of $7.7 million, a net profit margin of −109.2%. Diluted earnings per share came to −$0.12.
See the XLAB stock overview for the latest quote and news, or the XLAB chart for price history and technical indicators.
XLAB income statement FAQ
What is Exascale Labs's annual revenue?
Exascale Labs reported total revenue of $7.0 million for fiscal year 2025, which ended on June 30, 2025. That was up 431.8% from $1.3 million the previous year.
Is Exascale Labs profitable?
No. Exascale Labs reported a net loss of $7.7 million in fiscal 2025, a net profit margin of −109.2%; its operating margin was −43.4%.
What is Exascale Labs's gross margin?
Exascale Labs's gross margin was 15.8% in fiscal 2025: for every $100 of revenue, Exascale Labs kept $16 after the direct cost of its products and services.
How much does Exascale Labs spend on research and development?
Exascale Labs spent $2.8 million on research and development in fiscal 2025, 39.9% of revenue.
What are Exascale Labs's earnings per share?
Exascale Labs earned $-0.12 per diluted share in fiscal 2025.
When does Exascale Labs's fiscal year end?
Exascale Labs's fiscal year ends in June. The latest annual report covers the year ended June 30, 2025.